Aptahem (APTA) Q3 2025 earnings summary

Executive summary

• Focused on advancing toward a potential US listing, cost discipline, regulatory initiatives, and business development during the quarter.

• Strategic steps included applying to FDA PreCheck and CNPV pilot programs, and initiating a US provisional patent application.

• Strengthened IP position with preliminary patent approval in China and ongoing US patent activities.

Financial highlights

• Operating income for Q3 2025 was 303 KSEK, down from 646 KSEK year-over-year.

• Result after financial items for Q3 was -1,387 KSEK (vs. -1,190 KSEK last year); EPS was -0.08 SEK (vs. -0.21 SEK).

• For the nine months, operating income was 1,756 KSEK (vs. 3,053 KSEK), and result after financial items was -4,785 KSEK (vs. -5,716 KSEK); EPS -0.21 SEK (vs. -1.01 SEK).

• Cash and cash equivalents at period end were 282 KSEK (vs. 1,173 KSEK).

Outlook and guidance

• Continued strict cost discipline and prioritization of core activities.

• Ongoing work on US listing process, international IR strategy, and regulatory preparations for FDA interactions.

• Focus on deepening partnership dialogues and strengthening the IP portfolio.